MoonLake Immunotherapeutics (MLTX) Change in Cash (2021 - 2026)

MoonLake Immunotherapeutics' Change in Cash history runs 6 years deep, the most recent figure standing at -$36.0 million for Q1 2026.

• On a quarterly basis, Change in Cash fell 139.53% year-over-year to -$36.0 million in Q1 2026; TTM through Mar 2026 was $26.9 million, a 114.41% increase from a year earlier, with the FY2025 full-year figure at $154.1 million, up 156.91% from the prior year.
• Change in Cash declined to -$36.0 million in Q1 2026 per MLTX's latest filing, from -$16.2 million in the prior quarter.
• Across five years, Change in Cash topped out at $451.7 million in Q2 2023 and bottomed at -$195.2 million in Q4 2024.
• The 5-year median for Change in Cash is $7.3 million (2024), against an average of $17.1 million.
• Across the five-year window, Change in Cash plunged 3259.8% in 2022 and surged 7928.12% in 2023, its largest moves.
• Year by year, Change in Cash stood at -$1.7 million in 2022, then jumped by 7928.12% to $133.0 million in 2023, then plunged by 246.79% to -$195.2 million in 2024, then soared by 91.69% to -$16.2 million in 2025, then slumped by 122.13% to -$36.0 million in 2026.
• Per Business Quant, the three latest MLTX Change in Cash figures stand at -$36.0 million (Q1 2026), -$16.2 million (Q4 2025), and $44.1 million (Q3 2025).